MARKET

ALGS

ALGS

Aligos Therapeutics, Inc.
NASDAQ
1.115
+0.005
+0.45%
Closed 16:00 03/29 EDT
OPEN
1.140
PREV CLOSE
1.110
HIGH
1.190
LOW
1.060
VOLUME
44.06K
TURNOVER
36.95K
52 WEEK HIGH
2.410
52 WEEK LOW
0.8401
MARKET CAP
47.88M
P/E (TTM)
-0.4953
1D
5D
1M
3M
1Y
5Y
Aligos Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga · 03/14 14:48
SVB Securities Sticks to Its Hold Rating for Aligos Therapeutics (ALGS)
TipRanks · 03/13 05:45
Aligos Therapeutics GAAP EPS of -$0.51 misses by $0.02, revenue of $3.54M beats by $1.39M
Seeking Alpha · 03/09 21:46
Earnings Scheduled For March 9, 2023
Benzinga · 03/09 13:00
A Preview Of Aligos Therapeutics's Earnings
Benzinga · 03/08 18:01
EcoR1 Capital Increases Position in Aligos Therapeutics (ALGS)
NASDAQ · 02/13 13:27
Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce
Benzinga · 02/09 16:39
Aligos Therapeutics in portfolio reorganization focused on NASH, COVID assets
Seeking Alpha · 02/08 22:44
More
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD), and cirrhosis, end-stage liver disease (ESLD). It has developed a portfolio of differentiated drug candidates for CHB, including a small molecule Capsid Assembly Modulator (CAM) and oligonucleotides (Antisense Oligonucleotides (ASO) and Small Interfering Ribonucleic Acids (siRNA)), each of which is designed against clinically validated targets in the Hepatitis B Virus (HBV) life cycle. Its pipeline includes ALG 000184 (CAM) for CHB; ALG 020572 (ASO) for HBV; ALG 055009 for the treatment of nonalcoholic steatohepatitis (NASH), and ALG-125755.

Webull offers kinds of Aligos Therapeutics Inc stock information, including NASDAQ:ALGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALGS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALGS stock methods without spending real money on the virtual paper trading platform.